Haoxi Health Technology LTD (HAO) — SEC Filings

Overview

Haoxi Health Technology LTD (HAO) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 6-K filed on Dec 3, 2025: On November 26, 2025, Haoxi Health Technology Limited entered into a Securities Purchase Agreement with several non-U.S. Persons. The filing does not disclose the specific dollar amounts or terms of this agreement, but it is classified as a material agreement.

Sentiment Summary

Across 20 filings, the sentiment breakdown is: 2 bullish, 17 neutral, 1 mixed. The dominant filing sentiment for Haoxi Health Technology LTD is neutral.

Filing Type Overview

Haoxi Health Technology LTD (HAO) has filed 18 6-K, 2 20-F with the SEC between Jan 2024 to Dec 2025.

Filings by Year

2025 · 2024

Recent Filings (20)

• 6-K Filing — 6-K · Dec 10, 2025
• Haoxi Health Enters Securities Purchase Agreement — 6-K · Dec 3, 2025 Risk: medium
  On November 26, 2025, Haoxi Health Technology Limited entered into a Securities Purchase Agreement with several non-U.S. Persons. The filing does not disclose t
• 6-K Filing — 6-K · Nov 12, 2025
• Haoxi Health Technology Closes Private Placement — 6-K · Oct 24, 2025 Risk: low
  Haoxi Health Technology Limited announced the closing of a private placement on October 24, 2025. This follows a previous disclosure of the private placement on
• Haoxi Health Navigates China's Regulatory Maze Amidst Share Consolidation — 20-F · Oct 20, 2025 Risk: high
  Haoxi Health Technology Ltd. (HAO) reported its fiscal year ended June 30, 2025, operating as an online marketing solution provider in China, primarily for the
• Haoxi Health Enters Private Placement Agreement — 6-K · Oct 17, 2025 Risk: medium
  On October 13, 2025, Haoxi Health Technology Limited entered into a securities purchase agreement (SPA) with certain non-U.S. investors for a private placement.
• Haoxi Health Tech Files 6-K with Financials — 6-K · Apr 23, 2025 Risk: low
  Haoxi Health Technology Ltd. filed a Form 6-K on April 23, 2025, to report its unaudited condensed consolidated financial statements for the six months ended De
• Haoxi Health CFO Resigns — 6-K · Apr 14, 2025 Risk: medium
  Haoxi Health Technology Limited announced on April 10, 2025, that its Chief Financial Officer, Ms. Yu Guo, has resigned from her position due to personal reason
• Haoxi Health Technology Holds Annual General Meeting — 6-K · Jan 14, 2025 Risk: low
  Haoxi Health Technology Limited held its annual general meeting (AGM) on January 10, 2025, both online and in person at its Beijing office. The meeting was cond
• Haoxi Health Technology Announces Annual General Meeting — 6-K · Dec 19, 2024 Risk: low
  Haoxi Health Technology Limited filed a Form 6-K on December 19, 2024, to announce its upcoming Annual General Meeting. Attached as exhibits are the Notice of t
• Haoxi Health Tech Exchanges Series A Warrants — 6-K · Nov 27, 2024 Risk: medium
  On November 27, 2024, Haoxi Health Technology Limited entered into a warrant exchange agreement with holders of 3,998,000 Series A warrants. This agreement allo
• Haoxi Health Tech Gets Nasdaq Bid Price Warning — 6-K · Nov 6, 2024 Risk: medium
  Haoxi Health Technology Limited (NASDAQ: HAO) received a notification from Nasdaq on November 6, 2024, indicating a deficiency in meeting the minimum bid price
• Haoxi Health Technology Files 2024 Annual Report — 20-F · Oct 29, 2024 Risk: medium
  Haoxi Health Technology Ltd. filed its annual report on Form 20-F for the fiscal year ended June 30, 2024. The company, incorporated in E9 and headquartered in
• Haoxi Health Technology CFO Resigns — 6-K · Sep 25, 2024 Risk: medium
  On September 25, 2024, Haoxi Health Technology Limited announced that its Chief Financial Officer, Mr. Bo Lv, has resigned from his position due to personal rea
• Haoxi Health Technology Closes Follow-On Offering — 6-K · Sep 23, 2024 Risk: medium
  On September 20, 2024, Haoxi Health Technology Limited closed an underwritten follow-on offering of 4,000,000 units. The filing does not specify the price per u
• Haoxi Health Tech Files 6-K for FY23 Results — 6-K · May 31, 2024 Risk: low
  Haoxi Health Technology Limited filed a Form 6-K on May 31, 2024, to report its financial results for the six months ended December 31, 2023. The filing also di
• Haoxi Health Enters Rebate Agreement — 6-K · May 7, 2024 Risk: low
  On April 29, 2024, Haoxi Health Technology Limited, through its subsidiary Beijing Haoxi Digital Technology Co., Ltd., entered into a Bidding Data Promotion Reb
• Haoxi Health Enters Media Platform Cooperation Deal — 6-K · May 3, 2024 Risk: low
  On April 28, 2024, Haoxi Health Technology Limited, through its subsidiary Beijing Haoxi Digital Technology Co., Ltd., entered into a Framework Contract for Coo
• Haoxi Health Technology: Underwriters Exercise Over-Allotment Option — 6-K · Mar 8, 2024 Risk: medium
  On March 8, 2024, EF Hutton LLC, representing the underwriters, fully exercised their over-allotment option for Haoxi Health Technology Limited. This involved p
• Haoxi Health (HAO) Closes $9.6M IPO, Shares Trading on Nasdaq — 6-K · Jan 30, 2024
  Haoxi Health Technology Limited (HAO) successfully closed its Initial Public Offering (IPO) on January 30, 2024, issuing 2,400,000 Class A ordinary shares at $4

Risk Profile

Risk Assessment: Of HAO's 17 recent filings, 1 were flagged as high-risk, 9 as medium-risk, and 7 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.

Key Executives

• Zhen Fan
• Yu Guo
• Bo Lv

Industry Context

Haoxi Health Technology operates in China's online marketing solutions sector, with a specific focus on the healthcare industry. This sector is characterized by rapid digital adoption but also faces increasing regulatory scrutiny. The competitive landscape likely includes both domestic and international players vying for advertising budgets from healthcare providers and pharmaceutical companies.

Top Tags

private-placement (2) · capital-raise (2) · sec-filing (2) · cfo-change (2) · resignation (2) · corporate-governance (2) · shareholder-meeting (2) · nasdaq (2) · material-agreement (1) · securities-purchase (1)

Key Numbers

• Total gross proceeds from IPO: $11,040,000 — Received from IPO and over-allotment option exercise on January 30, 2024, and March 8, 2024
• Total Class A Ordinary Shares sold in IPO: 2,760,000 — Including 2,400,000 in IPO and 360,000 from over-allotment option
• IPO price per share: $4.00 — Price at which Class A Ordinary Shares were sold in the IPO
• Advertiser customers in FY2025: 473 — Decrease from 543 in FY2024, but increase from 393 in FY2023
• Healthcare advertiser customers in FY2025: 414 — Representing the majority of customers served
• Share consolidation ratio: 25:1 — Effected on January 10, 2025, for Class A and Class B Ordinary Shares
• Post-consolidation par value per share: $0.0025 — For both Class A and Class B Ordinary Shares after January 10, 2025
• Total ordinary shares outstanding as of June 30, 2025: 2,896,595 — Including 2,205,795 Class A and 690,800 Class B ordinary shares
• Series A Warrants: 3,998,000 — Number of warrants involved in the exchange agreement
• Minimum Bid Price: $1.00 — The minimum price per share required by Nasdaq for continued listing.
• Compliance Period: 180 days — The timeframe Haoxi Health Technology Limited has to meet the minimum bid price requirement.
• Fiscal Year End: 20240630 — The period covered by the annual report
• Filing Date: 20241029 — The date the 20-F was submitted to the SEC
• Units Offered: 4,000,000 — Represents the total number of units sold in the follow-on offering.
• Shares: 360,000 — Additional Class A ordinary shares purchased by underwriters due to over-allotment option exercise.

Related Companies

HAOX

Frequently Asked Questions